反应详情

According to General Protocol III/Step A & B, 5-bromo-2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzamide (1.5 g, 3.69 mmol), 27% aqueous ammonium hydroxide, and 4-[4-(1-methylethyl)-1-piperazinyl]-2-(methyloxy)aniline (0.550 g, 3.32 mmol) were combined to afford 5-bromo-2-({2-{[4-[4-(1-methylethyl)-1-piperazinyl]-2-(methyloxy)phenyl]amino}-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzamide as a pale yellow solid (1.78 g). An aliquot of 5-bromo-2-({2-{[4-[4-(1-methylethyl)-1-piperazinyl]-2-(methyloxy)phenyl]amino}-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzamide (0.340 g) was detosylated according to the General Protocol III/Step C to afford 5-bromo-2-[(2-{[4-[4-(1-methylethyl)-1-piperazinyl]-2-(methyloxy)phenyl]amino}-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide (0.204 g, 58% yield, 3 steps); 1H NMR (400 MHz, DMSO-d6) δ ppm 0.98 (d, J=6.41 Hz, 6H), 2.56 (s, 4H), 2.63 (d, J=6.23 Hz, 1H), 3.07 (s, 4H), 3.26 (s, 3H), 6.19 (dd, J=3.30, 1.83 Hz, 1H), 6.45 (d, J=8.97 Hz, 1H), 6.59 (d, J=2.01 Hz, 1H), 6.91 (d, J=2.20 Hz, 1H), 7.41 (s, 1H), 7.51 (dd, J=9.06, 2.29 Hz, 1H), 7.75-7.84 (m, 2H), 7.96 (d, J=2.20 Hz, 1H), 8.35 (s, 1H), 8.88 (d, J=8.97 Hz, 1H), 11.26 (s, 1H), 11.85 (s, 1H). ESIMS (M+H)+=580.